Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Why isn’t Ozempic on Australia’s Pharmaceutical Benefits Scheme for weight loss? And should it be?

The drug is subsidised for treatment of type 2 diabetes but experts say it could help reduce other health problems associated with severe obesity

The Guardian - AU

Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Investors Business Daily

Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

MarketBeat

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review

The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy signals.

Investors Business Daily

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Investors Business Daily

Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly

Eli Lilly stock has been struggling since mid-August and could provide a nice bearish candidate.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

The Conversation

Stock Market Today: Stocks Are Mixed Ahead of CPI

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

Kiplinger

Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow

Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.

Investors Business Daily

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

MarketBeat

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

Barchart

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly is scheduled to release its Q4 earnings report next month, and analysts forecast triple-digit profit growth.

Barchart

Arianna Huffington's Thrive Global partners with Eli Lilly

Patients can watch a video on how to de-stress in the same place they fill their prescriptions.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How Richard DiMarchi Revolutionized Diabetes Treatment

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

Barchart

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

Barchart

Is Eli Lilly Stock a Buy, Sell, or Hold for 2025?

Eli Lilly is very close to joining the $1 trillion club. Should you buy shares now?

USA Today Sports Media Group

All-Pro safety Brian Dawkins NFL’s defensive adjustments amid rule changes

All-Pro safety Brian Dawkins comments on how NFL defenses have adjusting to the league's changing rules w/ @EdEastonJr

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

8 Giant Stock Champs In 2024 Predicted To Win Again In 2025

Missed out on giant S&P 500 winners this year like Nvidia and Eli Lilly? Don't worry: Analysts think you'll get another shot in 2025.

MarketBeat

3 Big-Name Stocks Just Announced Big-Time Dividend Increases

Eli Lilly, plus two other massive companies, just announced double-digit percentage increases in their quarterly dividend payments.

Investors Business Daily

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Investors Business Daily

Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Investors Business Daily

IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.

MarketBeat

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

Investors Business Daily

Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

544 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.